Real-world effectiveness of systemic anticancer therapy for advanced melanoma in the west of Scotland from 2010 to 2018.

Autor:	Clarke J; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland.; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland., Bennie M; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland.; Public Health Scotland, Edinburgh, EH12 9EB, Scotland., Kurdi A; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland.; Department of Pharmacology & Toxicology, College of Pharmacy, Hawler Medical University, Erbil, Iraq., Pan J; Department of Mathematics & Statistics, University of Strathclyde, Glasgow, G1 1XH, Scotland., Mueller T; Strathclyde Institute of Pharmacy & Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, Scotland., Crearie C; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland., Baillie K; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland., Laskey J; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland., Waterston A; NHS Greater Glasgow & Clyde, Glasgow, G12 0XH, Scotland.
Jazyk:	angličtina
Zdroj:	Future oncology (London, England) [Future Oncol] 2023 Feb; Vol. 19 (6), pp. 451-461. Date of Electronic Publication: 2023 Apr 11.
DOI:	10.2217/fon-2022-0959
Abstrakt:	Aim: Assess the real-world effectiveness of systemic anticancer therapy in advanced (unresectable or metastatic) melanoma. Methods: This was a retrospective cohort study linking routine healthcare data with systemic anticancer therapy prescriptions for patients starting immunotherapy or targeted treatments between 1 November 2010 and 31 December 2017 in the west of Scotland. Results: Among 362 patients identified, median overall survival varied between 18.5 months (95% CI: 14.4-not estimable) for ipilimumab/nivolumab combination and 5.6 months (95% CI: 4.5-7.3) for dabrafenib, but there were differences in the characteristics of each regimen cohort. Raised lactate dehydrogenase levels and Eastern Cooperative Oncology Group performance status ≥2 negatively impacted overall survival. Conclusion: The patients had a shorter median overall survival than those in pivotal trials. This was expected, given that this real-world cohort included patients with poorer prognostic indicators, typically excluded from trials.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu